Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial

The Lancet Oncology
Giles W RobinsonPaul A Northcott

Abstract

Young children with medulloblastoma have a poor overall survival compared with older children, due to use of radiation-sparing therapy in young children. Radiotherapy is omitted or reduced in these young patients to spare them from debilitating long-term side-effects. We aimed to estimate event-free survival and define the molecular characteristics associated with progression-free survival in young patients with medulloblastoma using a risk-stratified treatment strategy designed to defer, reduce, or delay radiation exposure. In this multicentre, phase 2 trial, we enrolled children younger than 3 years with newly diagnosed medulloblastoma at six centres in the USA and Australia. Children aged 3-5 years with newly diagnosed, non-metastatic medulloblastoma without any high-risk features were also eligible. Eligible patients were required to start therapy within 31 days from definitive surgery, had a Lansky performance score of at least 30, and did not receive previous radiotherapy or chemotherapy. Patients were stratified postoperatively by clinical and histological criteria into low-risk, intermediate-risk, and high-risk treatment groups. All patients received identical induction chemotherapy (methotrexate, vincristine, cisplatin...Continue Reading

Citations

Jul 24, 2018·Expert Review of Neurotherapeutics·Carolina Nör, Vijay Ramaswamy
Oct 10, 2018·Current Opinion in Neurology·Didier FrappazMarc Barritault
Oct 4, 2018·Medical Sciences : Open Access Journal·Ugo TestaElvira Pelosi
Mar 6, 2019·Journal of Neurosurgery. Pediatrics·Ian F PollackAlberto Broniscer
May 28, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B W KristensenP Wesseling
Jul 13, 2019·Journal of Neuropathology and Experimental Neurology·Somak RoyMarina N Nikiforova
Sep 13, 2019·Pediatric Blood & Cancer·Amardeep S GrewalChristine Hill-Kayser
Oct 20, 2018·Current Cancer Drug Targets·Jia WeiJiayuh Lin
Oct 15, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthias BegemannIngo Kurth
Oct 2, 2019·Journal of Neurosurgery. Pediatrics·Kyle Juraschka, Michael D Taylor
Nov 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucie Lafay-CousinAmar Gajjar
Dec 5, 2019·Brain Pathology·Rahul KumarPaul A Northcott
Oct 29, 2019·British Journal of Clinical Pharmacology·John C PanettaClinton F Stewart
Dec 29, 2019·Brain Pathology·Randy Van OmmerenMichael D Taylor
Jan 18, 2020·Cancers·Jennifer L StripayChristopher L Tinkle
Apr 25, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin MynarekStefan Rutkowski
May 1, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giles W Robinson, Amar Gajjar
May 10, 2020·Pediatric Blood & Cancer·Sujith BaligaTorunn I Yock
Sep 27, 2019·Scientific Reports·Anup S PathaniaAnat Erdreich-Epstein
Sep 30, 2020·Expert Opinion on Therapeutic Targets·Ludovica Lospinoso SeveriniLucia Di Marcotullio
Mar 16, 2019·Science·E Alejandro Sweet-Cordero, Jaclyn A Biegel
Feb 26, 2020·Cancer Metastasis Reviews·Michelle M Kameda-Smith
May 30, 2019·Annals of Clinical and Translational Neurology·Otília Menyhárt, Balázs Győrffy
Feb 16, 2019·Nature Reviews. Disease Primers·Paul A NorthcottStefan M Pfister
Aug 4, 2019·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Eveline Teresa HidalgoSharon L Gardner
Jul 14, 2019·Nature Reviews. Cancer·David T W JonesStefan M Pfister
Aug 9, 2019·Cancer Chemotherapy and Pharmacology·Samuel J ReddickClinton F Stewart
Dec 11, 2019·Nature Reviews. Cancer·Volker HovestadtPaul A Northcott
Feb 14, 2020·Journal of Neuropathology and Experimental Neurology·Colleen E D'ArcyCynthia E Hawkins
Feb 2, 2019·The Journal of Clinical Investigation·David R Raleigh, Jeremy F Reiter
Jul 22, 2018·Nature Reviews. Clinical Oncology·Marc Remke, Vijay Ramaswamy
Jul 12, 2019·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Michelle M Kameda-SmithUNKNOWN Pediatric Brain Tumour Study Group
Apr 17, 2020·Nature·Sebastian M WaszakStefan M Pfister
Jun 11, 2020·Acta Neuropathologica·Kyle S SmithMartine F Roussel
Oct 23, 2020·Neuro-oncology·Martin Mynarek, Stefan Rutkowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.